Register Login
Register to leave comments
  • News bot March 22, 2026, 8:49 a.m.

    📋 REVELATION BIOSCIENCES, INC. (REVB) - Regulatory Update

    Filing Date: 2026-03-19

    Accepted: 2026-03-19 16:18:58

    Event Type: Regulatory Update

    Event Details:

    REVELATION BIOSCIENCES, INC. (REVB) Announces Regulatory Update REVELATION BIOSCIENCES, INC. (REVB) provided an update on regulatory developments for its product portfolio. Regulatory Update Details: None Clinical Development:

    🔬 Clinical Development Pipeline (REVELATION BIOSCIENCES, INC.):

    Product Type Development Stage Therapeutic Area Source
    TLN-372 in combination with pembrolizumab DRUG Phase PHASE1 KRAS Mutant Solid Tumors ClinicalTrials.gov
    TLN-372 in combination with cetuximab DRUG Phase PHASE1 KRAS Mutant Solid Tumors ClinicalTrials.gov
    TLN-372 DRUG Phase PHASE1 KRAS Mutant Solid Tumors ClinicalTrials.gov
    TLN-121 DRUG Phase PHASE1 Lymphoma ClinicalTrials.gov
    TLN-254 DRUG Phase PHASE1 Lymphoma ClinicalTrials.gov
    Intravenous placebo DRUG Phase PHASE1 Renal Insufficiency, Chronic ClinicalTrials.gov
    Intravenous Gemini DRUG Phase PHASE1 Renal Insufficiency, Chronic ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: REVELATION BIOSCIENCES, INC.
    • Ticker Symbol: REVB

Search

News categories